Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines

Treatment strategies involving tyrosine kinase inhibitors (TKIs) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations have advanced significantly; however, challenges still remain regarding the development of resistance. It has been reported tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui-Li, Liu, Yan-Chun, Long, Ming-Peng, Zheng, Chuan, Yang, Jia-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704288/
https://www.ncbi.nlm.nih.gov/pubmed/31452776
http://dx.doi.org/10.3892/ol.2019.10643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704288/
https://www.ncbi.nlm.nih.gov/pubmed/31452776
http://dx.doi.org/10.3892/ol.2019.10643

Ejemplares similares